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Immunization of BALB/c mice with a plasmid containing the gene for Trypanosoma cruzi trans-sialidase (TS)
induced antibodies that inhibited TS enzymatic activity, CD41 Th1 and CD81 Tc1 cells, and protective
immunity against infection. We used this model to obtain basic information on the requirement of CD4 or CD8
or B-cell epitopes for an effective DNA-induced immunity against T. cruzi infection. For that purpose, mice were
immunized with plasmids containing DNA sequences encoding (i) the entire TS protein, (ii) the TS enzymatic
domain, (iii) the TS CD41 T-cell epitopes, (iv) the TS CD81 T-cell epitope, or (v) TS CD41 and CD81 T-cell
epitopes. Plasmids expressing the entire TS or its enzymatic domain elicited similar levels of TS-inhibitory
antibodies, g interferon (IFN-g)-producing T cells, and protective immunity against infection. Although the
plasmid expressing TS CD4 epitopes was immunogenic, its protective efficacy against experimental infection
was limited. The plasmid expressing the CD8 epitope was poorly immunogenic and provided little protective
immunity. The reason for the limited priming of CD81 T cells was due to a requirement for CD41 T cells. To
circumvent this problem, a plasmid expressing both CD41 and CD81 T-cell epitopes was produced. This
plasmid generated levels of IFN-g-producing T cells and protective immunity comparable to that of the plasmid
expressing the entire catalytic domain of TS. Our observations suggest that plasmids expressing epitopes recognized
by CD41 and CD81 T cells may have a better protective potential against infection with T. cruzi.
Recently, independent groups studied the immunogenic
properties of plasmids containing genes encoding distinct an-
tigens expressed on the surface of infective forms of Trypano-
soma cruzi. This protozoan parasite causes Chagas’ disease, an
acute and chronic illness that afflicts between 16 and 18 million
people in Latin America. Immunization with plasmids contain-
ing T. cruzi genes generate immune responses mediated by
antibodies and CD41 and CD81 T cells. Most relevant, DNA-
vaccinated mice display remarkable protective immunity, sur-
viving lethal infection with T. cruzi (6, 28, 35). These observa-
tions argued that, in the short term, genetic vaccination might
be used as a valuable tool for the identification of antigens that
can elicit protective immune responses in humans against this
protozoan parasite. Also, in the long run, genetic vaccination
can be explored as a possible strategy for the development of
immunoprophylactic or therapeutic measures to fight this illness.
During Chagas’ disease, mice and humans develop parasite-
specific major histocompatibility complex (MHC) class I- and
MHC class II-restricted T cells (3, 7, 32, 37). These subpopu-
lations of T cells seem to complement each other to provide
optimal host resistance against infection. Genetically modified
knockout (KO) mice that do not express either MHC class I or
MHC class II antigens are highly susceptible to infection com-
pared to wild-type mice (31). CD4 or CD8 KO mice were also
highly susceptible to infection, emphasizing the importance of
both T-cell populations during naturally acquired immune re-
sponses (26).
Similarly to T. cruzi infection, we found that BALB/c mice
immunized with a plasmid containing a gene encoding the
catalytic domain of T. cruzi trans-sialidase (TS) and that had
been shown to be protected against a lethal challenge with
infective forms of the parasite developed immune responses
mediated by CD41 and CD81 T cells. From mice immunized
with the TS gene, we isolated CD41 Th1 and CD81 Tc1
clones. These clones displayed remarkable antiparasitic activ-
ities in vitro (23, 24).
Based on the observation that DNA immunization with the
TS gene could elicit distinct immunological mechanisms, we
considered that a detailed comparison of the immunogenicity
of plasmids containing either the entire TS gene or DNA
sequences encoding its immunogenic portions would be impor-
tant. From this type of study, we expected to obtain basic in-
formation on the requirement of CD4 or CD8 or B-cell epi-
topes for an effective DNA-induced immunity against T. cruzi.
For this purpose, we compared the levels of antibody response,
gamma interferon (IFN-g) secretion, and protective immunity
against experimental infection in mice immunized with plas-
mids containing DNA sequences encoding (i) the entire TS
protein, (ii) the TS enzymatic domain, (iii) TS CD41 T-cell
epitopes, (iv) the TS CD81 T-cell epitope, and (v) TS CD41
and CD81 T-cell epitopes.
MATERIALS AND METHODS
Plasmids. p154/13 contains the nucleotide sequence coding for amino acids
(aa) 1 to 678 of TS inserted into a commercially available plasmid, pcDNA3 (6).
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This region contains the signal peptide (aa 1 to 33) and the entire catalytic
domain of TS (aa 34 to 678; Table 1). pD154/13, pD154/13-CD8, and pcDNA3-
TS were generated by modifying p154/13. This plasmid was initially cut with
Xhol. This treatment removed a fragment of 1,209 bp located in the 39 region of
the TS gene. After separation in agarose gel, the higher-molecular-weight band
was excised from the gel and DNA purified with the aid of a Nucleiclean kit
(Sigma). This DNA was used to generate the other three plasmids. pD154/13 was
obtained by ligation of the DNA in the presence of T4 ligase and transformation
into competent Escherichia coli DH5a. This plasmid contains 825 bp coding for
the first 275 aa of TS. It includes the TS signal peptide (aa 1 to 33) and 242 aa of
the N-terminal region of the catalytic domain of TS (Table 1).
pD154/13-CD8 was generated by ligation of Xhol-treated DNA in the presence
of oligonucleotides 59-TCGA ATT TAT AAC GTT GGG CAA GTA TCC ATT
TAA-39 (forward) and 59-TCGA TTA AAT GGA TAC TTG CCC AAC GTT
ATA AAT-39 (reverse). (Underlined nucleotides represent the XhoI restriction
site.) After transformation, several colonies were screened by hybridization with
forward oligonucleotide labeled with [g32-P]ATP using T4 polynucleotide kinase.
The presence of a nucleotide sequence encoding the CD8 epitope was further
confirmed by direct sequencing analysis with the Thermosequenase cycle se-
quencing kit (Amersham) using the T7 primer label with [g-32P]ATP. This
plasmid contains 825 bp coding for the first 275 aa of TS and 27 bp coding for the
CD8 epitope of TS (Table 1).
The DNA containing the pcDNA3 and the 59 region of the TS gene was ligated
to an Xhol fragment obtained from the original TS 154 gene (34). This Xhol
fragment contained 2,358 bp encoding part of the TS catalytic domain, the
C-terminal repeats, and amino acids that are exchanged by the glycophosphati-
dylinositol anchor. After transformation, a colony was selected with a plasmid
containing the insert in the correct orientation. This plasmid contained the entire
coding region of the originally cloned TS 154 gene and was designated pcDNA3-
TS (Table 1).
We also generated a plasmid containing the sequence encoding the TS CD8
epitope preceded by an initiation code (MIYNVGOVSI). pcDNA3 was cut with
EcoRI and BamHI. After agarose gel separation, purified DNA was ligated in
the presence of the oligonucleotides 59-AATT ATG ATT TAT AAC GTT GGG
CAA GTA TCC ATT TAA-39 (forward) and 59-GATC TTA AAT GGA TAC
TTG CCC AAC GTT ATA AAT CAT-39 (reverse). After transformation, sev-
eral colonies were screened as described above by hybridization with labeled
forward oligonucleotide. The presence of a nucleotide sequence encoding the
CD8 epitope was further confirmed by direct sequencing (Table 1).
Parasites and animals. Female, 5-to-8-week-old BALB/c mice used in this
study were purchased from the University of Sa˜o Paulo. Bloodstream trypomas-
tigotes of the Y strain were obtained from 7-day infected mice. The blood was
collected from the axillary vein and transferred to a tube containing heparin.
After centrifugation, the parasites were collected in plasma, centrifuged, and
washed twice in phosphate-buffered saline (PBS). The concentration of parasites
was estimated and adjusted to 32,500 per ml. Each mouse was inoculated intra-
peritoneally (i.p.) with 0.2 ml (6,500 trypomastigotes). Parasite development was
monitored in the blood according to the standard method (14).
DNA immunization. Plasmids were produced in E. coli DH5a and purified on
cesium chloride density gradients as described earlier (6). DNA concentration
was estimated at 260 nm and confirmed by agarose gel stained with ethidium
bromide. Each plasmid DNA was diluted in sterile PBS to a concentration of 1
mg/ml. BALB/c mice were immunized according to a protocol described earlier
(6). Both tibialis anterioris muscles were injected with 3.5 mg of cardiotoxin
(Sigma). Five days later, 50 mg of plasmid DNA was injected intramuscularly
(i.m.) at the same sites as for cardiotoxin injection (a total of 100 mg of plasmid
DNA per mouse). The subsequent doses consisted of the same amount of
plasmid DNA injected 3, 5, and 7 weeks after the first dose. Experiments of DNA
immunization and infection with T. cruzi were reproduced at least three times
with similar results.
Statistical analysis. The Student’s and alternate t tests were used to compare
the possible differences in the mean values of peak parasitemia. Fisher’s exact
test was used to compare the frequencies of mice that survived T. cruzi infection.
The differences were considered significant when the P value was ,0.05.
Recombinant protein and detection of antibodies to TS. The recombinant TS
catalytic domain (TS-cat) was produced in E. coli transformed with plasmid
TS-cat7 as described earlier in detail (22). This protein contains the entire
catalytic domain of the enzyme including aa 34 to 678. The purity of recombinant
TS-cat was determined by sodium dodecyl sulfate–10% polyacrylamide gel elec-
trophoresis. A single band of 70 kDa was visualized in the gel. Protein concen-
tration was estimated by the Bradford procedure (Bio-Rad).
Anti-TS antibodies were detected by enzyme-linked immunosorbent assay
(ELISA) using polystyrene flat-bottom microtiter plates coated with recombi-
nant TS-cat. Each well was incubated overnight at 4°C with 200 ng of protein
dissolved in 0.05 ml of 0.1 M NaHCO3, pH 8.5. Unbound antigen was removed
by washing with PBS (pH 7.4) containing 0.05% Tween 20 (PBS-Tween). Wells
were treated with 2% bovine serum albumin (BSA) and 5% dry nonfat milk in
PBS (PBS-BSA). After 2 h, 50 ml of the sera from immunized and control mice
at the indicated dilutions were incubated for 60 min at 37°C. After five washes
with PBS-Tween, wells were incubated for 30 min at 37°C with anti-mouse
immunoglobulin G (IgG) (heavy and light chain) conjugated to peroxidase di-
luted 1:4,000, and bound immunocomplexes were detected with o-phenylenedi-
amine. Plates were read at 492 nm on an ELISA reader.
The presence of antibodies that inhibit TS activity was detected essentially as
described earlier (6). The final concentration of serum was 1:10. TS activity was
determined by the transfer of sialic acid from sialyllactose to D-glucose-1-[14C]
lactose (Amersham) and detection of the radioactive sialylated products by
chromatography on QAE-Sephadex A-25. The results were obtained as counts
per minute of [14C]-sialyllactose formed and are presented as the percent inhi-
bition of enzymatic activity calculated as follows: percent inhibition 5 [(X 2
Blank)/(A 2 Blank) 2 1] 3 100, where X is the radioactivity of the enzyme when
incubated in the presence of sera from immunized mice, Blank is the radioac-
tivity in the absence of the enzyme, and A is the radioactivity of the reaction
obtained in the presence of the enzyme without any sera.
Synthetic peptide. The synthetic peptide IYNVGQVSI (TS359–367) was pur-
chased from Neosystem (Strasbourg, France). As estimated by high-performance
liquid chromatography analysis, it was more than 90% pure. This peptide rep-
resents aa 359 to 367 encoded by the TS 154 gene (34).
Cell-mediated immune response assays. (i) Cell cultures. As culture medium
we used RPMI 1640 supplemented with 10 mM HEPES, 2 mM L-glutamine, and
100 U of penicillin and streptomycin (Sigma) per ml. For stimulation of the
spleen cells, we added to the medium 5 3 1025 M 2-mercaptoethanol, 1 mM so-
dium pyruvate, 1% nonessential amino acid solution, a 1% dilution of a vitamin
solution, 10% (vol/vol) fetal calf serum (Hyclone), and 30 U of recombinant
human interleukin-2 (kindly provided by Hoffmann-LaRoche) per ml. Cultures
were maintained at 37°C in an atmosphere containing 5% CO2.
(ii) IFN-g secretion by spleen cells stimulated with transfected or peptide-
coated A20J cells. Responder cells were obtained from spleens of DNA-immu-
nized mice 2 to 6 weeks after the last immunization. Stimulator cells were mouse
lymphoma A20J cells that express MHC class I and II molecules. These cells
TABLE 1. Characteristics of the plasmids used for DNA immunization
Plasmid Base pairsa Amino acids TS region(s)
pcDNA3-TS 1–3180 1–1060 Entire protein
p154/13 1–2034 1–678 Signal peptide, catalytic domain
pD154/13 1–825 1–275 Signal peptide, part of the catalytic domain (CD4 epitopes)
pCD8-epitope 1077–1101 359–367 CD8 epitope
pD154/13-CD8 1–825 1–275 Signal peptide, part of the catalytic domain and CD8 epitope
1077–1101 359–367
pcDNA3 None None None
a Based on the sequence of TS 154 gene (31).
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were kindly provided by M. Tsuji from New York University. Transfected A20J-
TS cells were generated and maintained as described earlier (23). Spleen cells
(4 3 107 cells per 10 ml) were expanded in vitro in the presence of 4 3 106
irradiated A20J-TS cells. After 6 days in culture, cells were extensively washed
and counted and their concentration was adjusted to 1.25 3 106 cells/ml. One
hundred microliters of this suspension containing 1.25 3 105 cells was incubated
with 105 irradiated A20J cells. These cells were (i) control A20J cells transfected
with pcDNA3 (A20J-pcDNA3), (ii) A20J-TS, (iii) control A20J cells, and (iv)
A20J cells coated with a 1 mM concentration of peptide TS359–367. These cells
were cultured in triplicate using 96-well flat-bottom plates in a final volume of 0.2
ml. After 18 h, the supernatants were collected and IFN-g was estimated by
capture ELISA.
The capture and detection monoclonal antibodies (MAbs) were R46A2 and
biotinylated XMG1.2, respectively (both were purchased from Pharmingen, San
Diego, Calif.). High-binding microtiter plates were coated with 0.05 ml of cap-
ture MAb (5 mg/ml) diluted in PBS and incubated overnight at 4°C. After washes
with PBS-Tween, wells were blocked with PBS-BSA for 2 h at room temperature.
After removing the blocking solution, 0.05 ml of T-cell supernatant was added
per well. Supernatants were diluted twice or up to 10 times in order to estimate
precisely the cytokine concentration. Each determination was performed in trip-
licate. After overnight incubation at 4°C, plates were washed and biotinylated
MAb was added at a final concentration of 5 mg/ml in PBS-BSA. After washes,
0.05 ml of avidin-peroxidase diluted in PBS-BSA was added to each well at a final
concentration of 2 mg/ml. After a 2-h incubation at room temperature, excess
labeled avidin-peroxidase was removed during washing and the reaction was
developed with o-phenylenediamine. The concentration of cytokine in each sam-
ple was determined from standard curves executed in parallel with a known
concentration of recombinant IFN-g (Pharmingen). The detection limit of the
assays was 0.2 ng/ml.
In vivo depletion of CD41 and CD81 T cells. Depletion of CD41 or CD81
cells was performed essentially as described previously (15). The hybridomas
producing rat IgG anti-CD4 (GK1.5) or anti-CD8 (2.43) were purchased from
the American Type Culture Collection. Ascites were produced in BALB/c nude
mice and precipitated with 35% (wt/vol) ammonium sulfate. After centrifuga-
tion, the pellet was resuspended in PBS extensively dialyzed against this buffer.
The concentration of rat IgG was estimated by radioimmunoassay using mouse-
absorbed anti-rat IgG (Kirkegaard & Perry Laboratories). For three consecutive
days, each mouse received daily doses of 1 mg of anti-CD4 or anti-CD8 MAb.
DNA immunization was performed 2 days after the last dose. The efficacy of the
depletion was estimated by flow cytometry analysis using anti-CD4 or anti-CD8
antibody followed by fluorescein-conjugated anti-rat IgG. The amount of CD41
cells was reduced by ;97% in mice treated with anti-CD4 MAb. Treatment with
anti-CD8 MAb eliminated 95% of CD81 cells.
RESULTS
Comparison of the immunogenicity and protective immu-
nity elicited by plasmids containing the entire TS gene or the
sequence encoding its enzymatic domain. In earlier studies,
we reported that protective immunity against experimental
T. cruzi infection in BALB/c mice could be generated by im-
munization with TS plasmid 154/13 (p154/13). This plasmid
contains the coding region for the catalytic domain of the
enzyme preceded by amino acids representing the signal pep-
tide of TS. In addition to the enzymatic domain, TS expressed
in trypomastigotes of T. cruzi has a C-terminal repeat domain
and is linked to the membrane by a glycophosphatidylinositol
anchor (27). A schematic description of the amino acid de-
duced primary structure of TS is shown in Fig. 1.
To determine whether immunization with the entire TS gene
could modify (improve or reduce) immunity to the functional
catalytic domain of the enzyme, we immunized mice with a
plasmid containing the entire TS gene (pcDNA3-TS; Table 1).
In the sera of BALB/c mice immunized with p154/13 and
pcDNA3-TS, we detected similar antibody titers to recombi-
nant TS-cat (Fig. 2A). Comparison of antibody titers after each
plasmid immunization also failed to reveal significant differ-
ences between mice immunized with p154/13 or pcDNA3-TS
(data not shown).
In addition to inducing antibodies that recognize recombi-
nant TS-cat by ELISA, immunization with these plasmids elic-
ited antibodies that significantly inhibited TS enzymatic activity
in vitro (Fig. 2B). Titration curves performed with pooled sera
collected from mice immunized with each plasmid also failed
to reveal a difference in the concentration of TS-inhibitory
antibodies (data not shown). In contrast, control mice immu-
nized with pcDNA3 did not present anti-TS antibodies as de-
termined by ELISA or inhibition of TS enzymatic activity (Fig.
2A and B, respectively).
The presence of IFN-g-producing cells in the spleens of
DNA-immunized mice was determined after in vitro expansion
of these cells by stimulation with A20J-TS cells. After 6 days of
expansion, spleen cells were restimulated in vitro with A20J-TS
cells or control A20J-pcDNA3 cells. Using this assay, we es-
tablished that CD41 and CD81 T cells were responsible for
IFN-g secretion (23). In parallel, spleen cells were restimu-
lated in vitro with A20J cells coated with peptide TS359–367,
which represents the TS CD8 epitope (23).
After restimulation with A20J-TS cells, spleen cells from
mice immunized with p154/13 or pcDNA3-TS produced com-
parable amounts of IFN-g (Fig. 2C). Upon restimulation in
vitro with A20J cells coated with peptide TS359–367, spleen cells
from mice immunized with p154/13 or pcDNA3-TS secreted
nearly identical amounts of IFN-g (Fig. 2C). This pattern was
observed in several independent experiments.
Protective immunity elicited by immunization with these two
plasmids was evaluated after a challenge with 6,500 blood-
stream trypomastigotes. The course of parasitemia and survival
of mice immunized with p154/13 or pcDNA3-TS were very
similar (Fig. 3A and B). These mice displayed a significantly
lower parasitemia than animals injected with pcDNA3 (P ,
0.001 at day 7; Fig. 3A). Also, almost all mice immunized with
TS plasmids survived infection. In contrast, a significant frac-
tion of animals injected with pcDNA3 died after challenge with
T. cruzi (P , 0.05; Fig. 3B).
Comparison of the immunogenicity and protective immu-
nity elicited by plasmids containing DNA sequences encod-
ing the TS enzymatic domain or its immunogenic epitopes. In
our earlier studies, we isolated CD41 Th1 and CD81 Tc1
clones from mice immunized with p154/13. These CD4 and
CD8 clones displayed remarkable antiparasitic activities in
vitro, inhibiting almost completely parasite replication in in-
fected macrophages or fibroblast cells, respectively (23, 24).
Using CD81 T-cell clones and synthetic peptides, it was pos-
FIG. 1. Schematic view of the primary structure of T. cruzi TS.
VOL. 69, 2001 EFFICIENT DNA-INDUCED IMMUNITY AGAINST T. CRUZI 5479
sible to precisely map the single CD8 epitope (TS359–367) rec-
ognized by these clones (Fig. 1 and reference 23). The epitope
recognized by the CD41 clones was partially mapped using
recombinant TS-cat protein and A20J cells transfected with
pD154/13. The recombinant TS-cat protein and pD154/13 ex-
press aa 34 to 678 and aa 1 to 275 of TS, respectively (reference
22 and Table 1). CD41 Th1 clones 2F1 and 2F3 secreted
IFN-g when stimulated with recombinant TS-cat protein or
A20J cells transfected with pD154/13 (reference 23 and unpub-
lished results, respectively). Based on these experiments, we
concluded that there is one or more CD4 epitopes located
between aa 34 and 275 of TS (Fig. 1). The identification of
these epitopes allowed us to determine the immunogenicity
FIG. 2. Immune responses of mice immunized with pcDNA3-TS
and p154/13. BALB/c mice were immunized as described in detail
in Materials and Methods with pcDNA3-TS (), p154/13 (n ), or
pcDNA3 (F). Fourteen days after the last immunization, blood sam-
ples were collected and the sera were assayed for the presence of
antibodies to TS by ELISA using polystyrene wells coated with recom-
binant TS-cat (A), or for the presence of TS-inhibitory antibodies (B).
The results represent the mean values obtained from eight mice 6 the
standard deviations (SD). Pooled spleen cells obtained from three
mice immunized with pcDNA3-TS, p154/13, or pcDNA3 were ex-
panded for 6 days in the presence of irradiated A20J-TS cells. (C) The
expanded cells were restimulated in the presence of A20J-pcDNA3,
A20J-TS, A20J cells, or A20J cells coated with 1 mM TS359-367 peptide
(A20J-TS359–367). IFN-g was estimated in supernatants collected after
18 h. Results are expressed as averages of triplicate cultures 6 SD.
FIG. 3. Trypomastigote-induced parasitemia and mortality in mice
immunized with pcDNA3-TS, p154/13, and pcDNA3. BALB/c mice
were immunized with pcDNA3-TS, p154/13, or pcDNA3. Three weeks
after the last immunization, mice were challenged i.p. with 6,500
bloodstream trypomastigotes. (A) Course of parasitemia, estimated as
described in Materials and Methods. The results represent the mean
values obtained from eight mice 6 the standard deviations. At the
peak of infection (day 7), the parasitemia of mice immunized with
pcDNA3-TS or p154/13 was significantly lower than the parasitemia of
control animals injected with pcDNA3 (p,0.001). (B) Kaplan-Meier
curves for survival of eight mice immunized with the indicated plas-
mid(s). Statistically significant survival was observed in mice immu-
nized with pcDNA3-TS or p154/13 compared to animals that received
pcDNA3 (P , 0.05).
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and protective efficacy of plasmids containing sequences en-
coding CD4 or CD8 epitopes of T. cruzi TS.
To evaluate the immunogenic properties of a plasmid con-
taining the sequence encoding the CD4 epitope(s) of TS, mice
were immunized with pD154/13. In parallel, we immunized
mice with p154/13, which expresses the catalytic domain of TS.
In the sera of mice immunized with pD154/13 or p154/13, we
detected similar antibody titers to recombinant TS-cat (Fig.
4A). Although immunization with pD154/13 elicited antibodies
that recognized very well the recombinant TS-cat by ELISA,
these antibodies did not inhibit TS enzymatic activity in vitro
(Fig. 4B). Increasing the serum concentration to 50% of the
final volume also failed to inhibit TS enzymatic activity (data
not shown).
The presence of IFN-g-producing cells in the spleens of
DNA-immunized mice was determined as described above. In
several independent experiments, upon restimulation with
A20J-TS cells, spleen cells from mice immunized with p154/13
produced higher amounts of IFN-g than cells from animals
immunized with pD154/13 (Fig. 4C). Also relevant was the fact
that spleen cells from mice that received pD154/13 did not
secrete IFN-g when restimulated in vitro with A20J cells
coated with peptide TS359–367 (Fig. 4C). This was expected
because this plasmid does not contain the sequence encoding
the TS CD8 epitope (Table 1).
In vitro experiments of T-cell depletion using anti-CD4 and
anti-CD8 MAbs in the presence of complement confirmed that
only IFN-g-producing CD41 T cells were present in animals
immunized with pD154/13. On the other hand, immunization
with p154/13 induced IFN-g-producing CD41 and CD81
T cells (data not shown and reference 23).
After challenge with T. cruzi trypomastigotes, the peak par-
asitemia of mice immunized with pD154/13 was extremely vari-
able in all three experiments performed. Nevertheless, the
course of parasitemia and number of mice immunized with
pD154/13 or pcDNA3 that survived the infection were not
statistically different (Fig. 5A and B, respectively). In contrast,
mice immunized with p154/13 had lower levels of parasitemia
than mice injected with pD154/13 or pcDNA3 (P 5 0.011 or
P , 0.001, respectively; Fig. 5A). Also, all p154/13-immunized
animals survived T. cruzi infection (Fig. 5B).
The immunogenicity and protective immunity generated by
a plasmid containing only the sequence encoding the TS CD8
epitope was determined in mice immunized with a plasmid
designated as pCD8-epitope (Table 1). IFN-g secretion by
spleen cells of mice immunized with pCD8-epitope was eval-
uated in vitro upon restimulation with A20J cells coated with
peptide TS359–367. IFN-g secretion was detected on several
occasions but was significantly lower than the concentration
detected in the supernatants of spleen cells from animals im-
munized with p154/13 (Fig. 6A).
The course of parasitemia and survival of mice immunized
with pCD8-epitope or p154/13 were also significantly different.
The peak parasitemia of pCD8-epitope-immunized mice was
higher than that of animals injected with p154/13 (P , 0.01;
Fig. 6B). Still, the peak parasitemia was slightly lower than in
control animals injected with pcDNA3 (P , 0.01). In spite of
the lower peak parasitemia, the mortality rates of mice injected
with pCD8-epitope or pcDNA3 were almost identical (Fig.
6C). In contrast, a significantly higher proportion of animals
immunized with p154/13 survived T. cruzi infection (P , 0.05;
Fig. 6C).
The limited priming and/or expansion of CD81 T cells by
immunization with CD8-epitope could be explained if these
cells required a concomitant activation of CD41 T cells. To
test this hypothesis, we treated mice with anti-CD4 or anti-
CD8 MAb before immunization with p154/13. In mice treated
with anti-CD4 MAb, we were unable to detect serum IgG
antibodies to recombinant TS-cat (Fig. 7A). In both experi-
ments, IFN-g secretion by CD41 or CD81 spleen cells was also
severely impaired (Fig. 7B). Treatment with anti-CD8 MAb
reduced IFN-g secretion after restimulation with A20J-TS
(Fig. 7B) and completely inhibited IFN-g secretion by spleen
cells specific for the TS359–367 peptide (Fig. 7B). These results
suggest that priming of B and CD81 T cells after immunization
with p154/13 was dependent on the presence of CD41 T cells.
To confirm that both CD4 and CD8 epitopes are required
for efficient DNA-induced immunity against T. cruzi, we im-
munized mice with pD154/13-CD8, which contains the se-
quence encoding both the CD4 and CD8 epitopes of TS (Table
1). In several experiments, we observed much lower antibody
titers to recombinant TS-cat in the sera of mice immunized
with pD154/13-CD8 than in mice injected with p154/13 (Fig.
8A). Also, these antibodies did not inhibit TS enzymatic activ-
ity in vitro (Fig. 8B).
Upon restimulation with A20J-TS cells, spleen cells from
mice immunized with pDp154/13 produced slightly lower
amounts of IFN-g than cells from animals immunized with
154/13-CD8 (Fig. 8C). This difference was observed in several
independent experiments. Lymphocytes from mice immunized
with pD154/13-CD8 and restimulated in vitro with A20J cells
coated with TS359–367 peptide secreted similar amounts of
IFN-g as cells from mice injected with p154/13 (Fig. 8C).
After challenge with T. cruzi trypomastigotes, the peak par-
asitemia of mice immunized with pD154/13-CD8 or p154/13
did not differ significantly from one another (P . 0.05; Fig. 9A)
and were significantly lower than the parasitemia of animals
injected with pcDNA3 (P , 0.001; Fig. 9A). A similar obser-
vation was made for mortality rate. While the majority of mice
injected with pcDNA3 died, all animals immunized with
pD154/13-CD8 or p154/13 survived a challenge with T. cruzi
trypomastigotes (P , 0.05; Fig. 9B).
DISCUSSION
The purpose of the present study was to compare the effec-
tiveness of immunization using various plasmids containing the
entire TS gene or sequences encoding its immunogenic por-
tions. We found that three distinct plasmids containing DNA
sequences encoding TS CD41 and CD81 T-cell epitopes could
provide a degree of immunity sufficient to reduce the para-
sitemia and mortality of DNA-immunized animals caused by a
challenge with T. cruzi trypomastigotes. In contrast, plasmids
expressing either CD41 or CD81 T-cell epitopes of TS were
unable to provide a similar degree of protective immunity
against infection.
The fact that acquired resistance to T. cruzi infection was
only effectively achieved by DNA immunization with plasmids
capable of generating both CD41 and CD81 T cells corrobo-
rates the findings of earlier study that used native paraflagellar
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rod proteins for immunization (18). In this study, a high degree
of protective immunity against T. cruzi infection was achieved
after immunization of wild-type and B-cell-deficient mice. On
the other hand, CD41 T-cell-depleted or b2-microglobulin KO
mice failed to control infection, indicating that CD41 and
MHC class I-restricted cells were important for protective im-
munity.
TS-specific CD41 T cells appear to play multiple roles in
immunity elicited by DNA immunization. In our system, it is
plausible that TS-specific CD41 T cells participate as an effec-
tor mechanism of protection. In mice immunized with p154/13,
CD41 T cells seem to be a major source of IFN-g, accounting
for ;65% of the IFN-g secreted by spleen cells in vitro (23).
FIG. 4. Immune responses of mice immunized with p154/13 and
pD154/13. BALB/c mice were immunized with p154/13, pD154/13, or
pcDNA3. Fourteen days after the last immunization, blood samples
were collected and the sera were assayed for the presence of antibodies
to recombinant TS-cat by ELISA (A) or for the presence of TS-
inhibitory antibodies (B). The results represent the mean value ob-
tained from eight mice 6 the standard deviations (SD). Pooled spleen
cells obtained from three mice immunized with p154/13, pD154/13, or
pcDNA3 were expanded for 6 days in the presence of irradiated
A20J-TS cells. (C) The expanded cells were restimulated in the pres-
ence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated with
1 mM TS359-367 peptide (A20J-TS359-367). IFN-g was estimated in su-
pernatants collected after 18 h. Results are expressed as averages of
triplicate cultures 6 SD.
FIG. 5. Trypomastigote-induced parasitemia and mortality in mice
immunized with p154/13, pD154/13, and pcDNA3. BALB/c mice were
immunized with p154/13, pD154/13, or pcDNA3. Three weeks after the
last immunization, mice were challenged i.p., with 6,500 bloodstream
trypomastigotes. (A) Course of infection, with the mean values ob-
tained from eight mice 6 the standard deviations. At the peak of
infection (day 8), the parasitemia of mice immunized with each plas-
mid were compared. The results were as follows: (i) p154/13 versus
pcDNA3, P , 0.001; (ii) p154/13 versus pD154/13, P 5 0.011; (iii)
pD154/13 versus pcDNA3, P . 0.05. (B) Kaplan-Meier curves for
survival of eight mice immunized with the indicated plasmid. Statisti-
cally significant survival was observed in mice immunized with p154/13
compared to animals that received pD154/13 or pcDNA3 (P , 0.05).
The number of mice immunized with pD154/13 or pcDNA3 that sur-
vived infection was not significantly different (P . 0.05).
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From DNA-vaccinated mice, we isolated CD41 Th1 clones
that efficiently activated macrophages to eliminate intracellular
forms of T. cruzi in vitro. The antiparasitic activity of macro-
phages activated by CD41 T cells was dependent on IFN-g and
FIG. 6. Immune response, trypomastigote-induced parasitemia,
and mortality of mice immunized with p154/13, pCD8-epitope, and
pcDNA3. BALB/c mice were immunized with p154/13, pCD8-epitope,
or pcDNA3. Fourteen days after the last immunization, pooled spleen
cells obtained from three mice immunized with each plasmid were
expanded for 6 days in the presence of irradiated A20J-TS cells. (A)
The expanded cells were restimulated in the presence of A20J-
pcDNA3, A20J-TS, A20J cells, or A20J cells coated with 1 mM peptide
TS359-367 (A20J-TS359-367). IFN-g was estimated in supernatants col-
lected after 18 h. Results are expressed as averages of triplicate cul-
tures 6 the standards of deviation (SD). Three weeks after the last
immunization, mice were challenged i.p. with 6,500 bloodstream try-
pomastigotes. (B) Course of infection, with mean values obtained from
eight mice 6 SD. At the peak of infection (day 7), the parasitemia of
mice immunized with each plasmid was compared. The results were as
follows: (i) p154/13 versus pcDNA3, P , 0.001; (ii) p154/13 versus
pCD8-epitope, P , 0.01; (iii) pCD8-epitope versus pcDNA3, P , 0.01.
(C) Kaplan-Meier curves for survival of eight mice immunized with the
indicated plasmid. Statistically significant survival was observed in mice
immunized with p154/13 compared to animals that received pCD8-epi-
tope or pcDNA3 (P , 0.05). The number of mice immunized with
pCD8-epitope or pcDNA3 that survived infection was not significantly
different (P . 0.05).
FIG. 7. Depletion of CD41 T cells significantly reduces TS-specific
antibodies and IFN-g-secreting CD41 and CD81 T cells induced by
immunization with p154/13. BALB/c mice were treated for three con-
secutive days with anti-CD4, anti-CD8, or rat-IgG. One and 22 days
later, these mice were immunized i.m. with 100 mg of p154/13. In
parallel, control mice received 100 mg of pcDNA3. (A) Fourteen days
after the last immunization, blood samples were collected and the sera
were assayed for the presence of antibodies to recombinant TS-cat by
ELISA The results represent the mean values obtained from four
mice 6 the standard deviations (SD). (B) Pooled spleen cells obtained
from two mice immunized with p154/13 and treated with anti-CD4,
anti-CD8, or rat-IgG were expanded for 6 days in the presence of
irradiated A20J-TS cells. The expanded cells were restimulated in the
presence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated
with 1 mM peptide TS359-367 (A20J-TS359-367). IFN-g was estimated in
supernatants collected after 18 h. Results are expressed as the average
of triplicate cultures 6 SD.
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nitric oxide production (24). Whether similar mechanisms op-
erate in vivo remains to be determined.
CD41 T cells can also participate in protective immunity by
providing help for antibody production. Mice immunized with
pcDNA3-TS or p154/13 produced antibodies that recognized
the catalytic domain of TS and drastically inhibited the activity
of this enzyme in vitro (Fig. 2A and B). The production of
antibodies specific for recombinant TS-cat was strictly depen-
dent on the activation of CD41 T cells because in mice treated
with anti-CD4 MAb, little or no specific antibodies were de-
tected (Fig. 7A). TS-inhibitory antibodies have the ability to
significantly reduce parasite sialylation in vitro (21). In vitro
studies also have suggested that the process of sialylation is
FIG. 8. Immune responses of mice immunized with p154/13 and
pD154/13-CD8. BALB/c mice were immunized with p154/13, pD154/
13-CD8, or pcDNA3. Fourteen days after the last immunization, blood
samples were collected and the sera were assayed for the presence of
antibodies to recombinant TS-cat by ELISA (A) or for the presence of
TS-inhibitory antibodies (B). Results represent the mean values ob-
tained from eight mice 6 the standard deviations (SD). (C) Pooled
spleen cells obtained from three mice immunized with p154/13, pD154/
13-CD8, or pcDNA3 were expanded for 6 days in the presence of
irradiated A20J-TS cells. The expanded cells were restimulated in the
presence of A20J-pcDNA3, A20J-TS, A20J cells, or A20J cells coated
with 1 mM TS359-367 peptide (A20J-TS359-367). IFN-g was estimated in
supernatants collected after 18 h. Results are expressed as the average
of triplicate cultures 6 SD.
FIG. 9. Trypomastigote-induced parasitemia and mortality in mice
immunized with p154/13, pD154/13-CD8, and pcDNA3. BALB/c mice
were immunized with p154/13, pD154/13-CD8, or pcDNA3. Three weeks
after the last immunization, mice were challenged i.p. with 6,500 blood-
stream trypomastigotes. (A) Course of infection and the mean values
obtained from eight mice 6 standard deviations. At the peak of infec-
tion (day 8). the parasitemia of mice immunized with each plasmid was
compared. The results were as follows: (i) p154/13 versus pcDNA3, P ,
0.001; (ii) p154/13 versus pD154/13-CD8, P . 0.05; (iii) pD154/13-CD8
versus pcDNA3, P , 0.001. (B) Kaplan-Meier curves for survival of
eight mice immunized with the indicated plasmid. Statistically signifi-
cant survival was observed in mice immunized with p154/13 or pD154/
13-CD8 compared to animals that received pcDNA3 (P , 0.01).
5484 FUJIMURA ET AL. INFECT. IMMUN.
important for parasite survival in the extracellular host envi-
ronment and during invasion of nonphagocytic cells (19). Most
relevant, an earlier study showed that passive transfer of anti-
bodies specific for the TS catalytic domain reduced mouse
infection with T. cruzi (4).
Although TS-inhibitory antibodies may participate in pro-
tective immune responses, immunity against T. cruzi infection
could be achieved in mice that had no TS-inhibitory antibodies.
Immunization with pD154/13-CD8 failed to induce TS-inhibi-
tory antibodies (Fig. 8B). Nevertheless, mice immunized with
this plasmid had a reduced parasitemia and mortality after
challenge with T. cruzi trypomastigotes (Fig. 9A and B). There-
fore, anti-TS antibodies may help but are not crucial for pro-
tective immunity generated by DNA immunization.
In spite of the activation of IFN-g-producing CD41 T cells,
in several experiments immunization of BALB/c mice with
pD154/13 failed to confer a significant degree of protective
immunity against T. cruzi infection. Two not-mutually-exclud-
ing possibilities could explain the lower efficacy of pD154/13.
First, CD41 T-cell activation could be reduced due to the loss
of CD4 epitopes present in the region spanning aa 276 to 678
of TS. Alternatively, activation of CD81 T cells could be im-
portant for efficient protective immunity against a lethal chal-
lenge with T. cruzi. To address the question of whether acti-
vation of CD81 T cells could restore the protective efficacy of
pD154/13, we generated pD154/13-CD8. Protective immunity
elicited by immunization with pD154/13-CD8 was similar to
that with p154/13, suggesting that activation of CD81 T cells
was crucial for protective immunity (Fig. 9A and B).
CD41 T cells induced by plasmid immunization seem to be
crucial for priming and expansion of specific CD81 T cells.
Immunization with pCD8-epitope was unable to efficiently
prime TS-specific CD81 T cells (Fig. 6A). In contrast, in mice
immunized with three distinct plasmids containing DNA se-
quences encoding both CD41 and CD81 T-cell epitopes,
IFN-g secretion by cells specific for peptide TS359-367 was sig-
nificantly higher. The importance of CD41 T cells in the prim-
ing of CD81 T cells was corroborated by the fact that in mice
treated with anti-CD4 MAb prior to immunization with p154/
13, IFN-g secretion by TS-specific CD81 T cells was undetect-
able (Fig. 7B).
Although several studies have reported immune responses
mediated by CD81 T cells after DNA immunization, only a
few studies have addressed the requirements for their priming.
In three studies, priming of specific CD81 T cells by DNA
immunization was compared in mice immunized with plasmids
containing minigenes encoding the CD8 epitope alone or in
the presence of sequences encoding a CD4 epitope. The ex-
pression of CD4 epitopes either restored or significantly im-
proved CD81 T-cell immune responses (8, 11, 17). These re-
sults suggested that in these cases CD81 T-cell priming
required the activation of CD41 T cells. In one of these stud-
ies, as in our case, depletion of CD41 T cells drastically re-
duced CD81 T-cell priming (17).
In other cases, however, priming of specific CD81 T cells
following DNA immunization with plasmids containing mini-
genes could also be achieved in the absence of CD41 T-cell
activation (2, 8, 11, 12, 25). These results are probably not
conflicting; rather, they may reflect different requirements for
CD81 T-cell priming observed after immunization with dis-
tinct epitopes. Very recent evidence has suggested that CD8
epitopes with very high affinities for MHC class I molecules
can efficiently prime CD81 T cells in MHC class II-deficient
mice (9). In contrast, priming of CD81 T cells with epitopes
with lower affinities for MHC class I molecules required the
coadministration of either a CD4 epitope or an anti-CD40
MAb (9).
In circumstances where priming of specific CD81 T cells
was observed with plasmids containing only minigenes encod-
ing CD8 epitopes, protective immunity against viral infection
could not be obtained (2, 8, 25). In one case, immunity was
observed against a bacterial infection (Listeria monocytogenes)
when using a plasmid expressing the CD8 epitope of listerio-
lysin (33). However, the degree of protective immunity was not
compared to that with plasmids containing the entire listerio-
lysin gene (5). In general, these observations suggested that
CD41 T cells induced by DNA immunization were important
either to provide optimal activation of CD81 T cells or as an
effector mechanism of protection, or both.
Although many studies have provided evidence that CD81 T
cells participate in the protective immunity against experimen-
tal T. cruzi infection, the precise mechanism used by these cells
has not been clearly defined. The fact that CD81 T cells se-
crete IFN-g may suggest that this is a mechanism leading to the
elimination of intracellular forms of the parasite. It is well
established that IFN-g is an important mediator of naturally
acquired immunity against the infection (10, 30). However, as
in the case of CD41 T cells, a direct link between the IFN-g
secretion by CD81 T cells and the in vivo antiparasitic activity
of these cells has not been provided.
In addition to producing IFN-g, CD81 T cells may exert
their antiparasitic effect by direct lysis of target cells infected
with T. cruzi or by secreting other potentially active mediators
such as tumor necrosis factor a, granulisin, or a number of
different chemokines (1, 20, 29). In fact, it has been described
that CD81 T cells specific for amastigote or trypomastigote
antigens are capable of lysing nonphagocytic cells infected with
T. cruzi in vitro (16, 36). However, it is unclear whether cytol-
ysis of infected target cells by CD81 T cells is an effective
mechanism to restrain T. cruzi infection in vivo. For example,
genetically modified mice that do not express perforin or gran-
zyme B are not more susceptible to infection than wild-type
animals (13). These observations argue against a crucial role
for perforin- or granzyme B-mediated lysis in resistance. The
elucidation of the antiparasitic mechanisms mediated by CD8
T cells will certainly require further investigation using more
accurate experimental models.
In summary, host acquired resistance to T. cruzi infection
was only effectively achieved by DNA immunization with plas-
mids of the TS gene capable of generating both CD41 Th1 and
CD81 Tc1 cells. It will be important to determine whether
activation of these two T-cell populations is also important
during protective immunity elicited by DNA immunization
with other T. cruzi genes (28, 35).
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